Acumen Pharmaceuticals (ABOS) Receivables - Net (2020 - 2021)

Acumen Pharmaceuticals (ABOS) reported Receivables - Net of $109000.0 for Q3 2021, little changed sequentially from $109000.0 in Q2 2021.

Acumen Pharmaceuticals (ABOS) Receivables - Net (2020 - 2021) Analysis & Trends

Acumen Pharmaceuticals (ABOS) has 2 years of Receivables - Net data on file, last reported at $109000.0 in Q3 2021.

For the quarter ending Q3 2021, Receivables - Net changed N/A year-over-year to $109000.0; the trailing twelve-month figure through Sep 2021 stood at $109000.0 (changed N/A YoY), and the FY2020 full-year result was $109000.0, changed N/A from the prior year.
Receivables - Net steadied at $109000.0 in Q3 2021, from $109000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $109000.0 in Q4 2020 to a low of $109000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,801.52 Bn	66,801.23 Bn	-
2	Nanobiotix	1,916.61 Bn	1,916.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.65 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.94 Bn	114.69 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.85 Bn	61.09 Bn	3.31 Bn
7	Belite Bio	63.06 Bn	63.06 Bn	-
8	Argenx Se	55.74 Bn	50.56 Bn	1.41 Bn
9	Revolution Medicines	37.48 Bn	37.48 Bn	-
10	Acumen Pharmaceuticals	141.30 Mn	141.30 Mn	-

Download Data